Form 4 for NTRA Natera, Inc.
Accepted 2026-02-04 00:00:00 ET · period of report 2026-02-02 · accession 0002010019-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-04 | 2026-02-02+ | NTRA | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | S - Sale | $231.20 | -4,639 | 137.8K | -3% | -$1.07M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-02 | S | D | 576 | $230.84 | 140,952 | D | — | — | (F1) The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. (F3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $230.6150 to $231.1400 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2026-02-02 | S | D | 878 | $229.96 | 141,528 | D | — | — | (F1) The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.5700 to $230.5150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-02-02 | S | D | 80 | $228.50 | 142,406 | D | — | — | (F1) The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. |
| 4 | Common | Common Stock | 2026-02-02 | S | D | 850 | $232.33 | 140,102 | D | — | — | (F1) The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. (F4) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $231.94 to $232.92 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2026-02-02 | S | D | 600 | $233.24 | 139,502 | D | — | — | (F1) The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. (F5) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $232.94 to $233.82 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2026-02-02 | S | D | 16 | $234.00 | 139,486 | D | — | — | (F1) The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. |
| 7 | Common | Common Stock | 2026-02-03 | S | D | 1,639 | $230.77 | 137,847 | D | — | — | (F6) The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025. |